3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025.

That's according to Piers Bolger, chief investment officer of Infinity Asset Management.

Commenting on the investment outlook for 2025, Bolger said, "Overall, the investment outlook for 2025 is positive but cautious."

He added:

Lower interest rates and strong equity dynamics present opportunities but risks like geopolitical tensions and uneven global growth require careful navigation. A flexible, growth-focused approach will be essential to manage challenges and seize opportunities.

Citing high valuations and declining earnings, Bolger said he's cautious on ASX 200 bank stocks.

But he has a positive outlook for the healthcare sector.

Happy healthcare workers in a lab.

Image source: Getty Images

ASX 200 healthcare stocks facing demand growth in 2025

Drilling into three specific ASX 200 healthcare stocks he's bullish on, Bolger named global pathology provider Sonic Healthcare Ltd (ASX: SHL), biotech giant CSL Ltd (ASX: CSL), and sleep disorder treatment company ResMed Inc (ASX: RMD).

"Companies like CSL, ResMed, and Sonic Healthcare are set to benefit from growing demand for pathology, blood plasma, and medical devices," he said. "These companies are trading at attractive prices and have strong return potential."

What's been happening with the Aussie healthcare companies?

ResMed reported its first quarter FY 2025 results on 25 October.

The ASX 200 healthcare stock gained 5.9% on the day after reporting an 11% year on year lift in revenue for the three months to 30 September of US$1.22 billion. 34% Operating profit was up 34% from the prior corresponding quarter.

Increased demand for the company's sleep devices and masks drove revenue growth. ResMed also reported growth across its Residential Care Software segment.

"Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business," ResMed CEO Mick Farrell said at the time.

ASX 200 healthcare stock Sonic reported its full FY 2024 results on 22 August.

Core financial metrics included a 9.8% year-on-year increase in revenue to $8.97 billion. Net profit after tax (NPAT) was down 25% from FY 2023 to $511 million.

"The 2024 financial year can be summarised as a transition period for Sonic Healthcare, as we moved away from the impacts of the pandemic towards business as usual," Sonic CEO Colin Goldschmidt said at the time.

As for CSL, the biotech company reported its FY 2024 results on 13 August.

The ASX 200 healthcare stock achieved an 11% year-on-year increase in revenue (in constant currency) to US$14.8 billion. And net profit after tax before amortisation was up 11% to US$2.91 billion.

"Our largest franchise, the immunoglobulins portfolio, delivered exceptional growth driven by significant patient demand, and the recovery in CSL Behring's gross margin is progressing to plan," CSL CEO Paul McKenzie said following the results.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »